Comparison · NCT01174160-9803ce56
Vernakalant IV vs Placebo: Proportion of Patients With Treatment-induced Conversion of Atrial Fibrillation to Sinus Rhythm
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vernakalant IV vs Placebo: Proportion of Patients With Treatment-induced Conversion of Atrial Fibrillation to Sinus Rhythm. Trial comparisons, record NCT01174160-9803ce56. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01174160-9803ce56
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.527 | 0.398 | 0.653 | wilson | |
| Risk in group 2 | 0.125 | 0.0619 | 0.236 | wilson | |
| Risk difference, group 1 minus group 2 | 0.402 | 0.232 | 0.543 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 4.22 | 2.02 | 8.81 | log | |
| Odds ratio, group 1 over group 2 | 7.81 | 3.01 | 20.2 | log | |
| Number needed to treat, for one more participant with the outcome on Vernakalant IV than on Placebo | 2.49 | 1.84 | 4.32 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vernakalant IV | vernakalant hydrochloride~Up to two 10-min infusions of 3mg/kg +/- 2mg/kg vernakalant IV | 29 | 55 | OG000 |
| Group 2 | Placebo | placebo~Up to two 10-min infusions of normal saline | 7 | 56 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Proportion of Patients With Treatment-induced Conversion of Atrial Fibrillation to Sinus Rhythm
- Description
- The proportion of patients with treatment-induced conversion of atrial fibrillation to sinus rhythm for a minimum duration of 1 minute
- Time frame
- Within 90 minutes after first exposure
- Population
Source ClinicalTrials.gov
Trial
- Title
- A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)
- NCT number
- NCT01174160
- Phases
- PHASE3
- Conditions
- Atrial Fibrillation
- Interventions
- vernakalant hydrochloride, Placebo to vernakalent hydrochloride
- Lead sponsor
- Advanz Pharma
- Results first posted
- 2015-12-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01174160?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01174160-9803ce56